Valion Bio, Inc. (VBIO) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 3.05M USD | Liabilities, Current |
| Cash and equivalents | 2.11M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 750.00K USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $3.05M | $2.11M | (m) | (m) | $750.00K | (m) |
| 2026-03-31 | (m) | $2.62M | $7.21M | (m) | (m) | $750.00K | (m) |
| 2025-12-31 | (m) | $646.00K | $12.64M | (m) | (m) | $0.00 | (m) |
| 2025-09-30 | (m) | $638.00K | $3.45M | (m) | $19.00K | $4.00K | (m) |
| 2025-06-30 | (m) | $821.00K | $1.18M | (m) | $13.00K | $283.00K | (m) |
| 2025-03-31 | (m) | $741.00K | $669.00K | (m) | $13.00K | $306.00K | (m) |
| 2024-12-31 | (m) | $272.00K | $2.00M | (m) | $69.00K | $319.00K | (m) |
| 2024-09-30 | (m) | $560.00K | $2.19M | (m) | $9.00K | $731.00K | (m) |
| 2024-06-30 | (m) | $591.00K | $3.69M | (m) | $16.00K | $766.00K | (m) |
| 2024-03-31 | (m) | $992.00K | $1.67M | (m) | $74.00K | $774.00K | (m) |
| 2023-12-31 | (m) | $1.40M | $3.40M | (m) | $174.00K | $756.00K | (m) |
| 2023-09-30 | (m) | $1.00M | $5.17M | (m) | $131.00K | $928.00K | (m) |
| 2023-06-30 | (m) | $1.16M | $2.66M | (m) | $13.00K | $988.00K | (m) |
| 2023-03-31 | (m) | $1.57M | $5.17M | (m) | $57.00K | $943.00K | (m) |
| 2022-12-31 | (m) | $1.86M | $3.52M | (m) | $88.00K | $863.00K | (m) |
| 2022-09-30 | (m) | $2.02M | $6.33M | (m) | $95.00K | $761.00K | (m) |
| 2022-06-30 | (m) | $2.38M | $9.05M | (m) | $92.00K | $833.00K | (m) |
| 2022-03-31 | (m) | $1.10M | $10.80M | (m) | $117.00K | $447.00K | (m) |
| 2021-12-31 | (m) | $1.22M | $12.97M | (m) | $92.00K | $429.00K | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |